Some of our press releases are protected by a log-in. These news are marked with a little padlock icon. How our medicines can be prescribed by doctors and the regulatory rules under which we operate differ between countries. Additionally, in most countries we are not permitted to advertise medicines to members of the public. Non-promotional information on our products can therefore only be accessed after registering with Daiichi Sankyo or by using your DocCheck login.
-
Daiichi Sankyo2023-11-09 21:01:17Daiichi Sankyo Announces Late-Breaking Phase 1 Dose Expansion Data for Patritumab Deruxtecan in Patients with
-
Daiichi Sankyo2020-09-15 15:08:35Daiichi Sankyo Initiates Phase 2 Study of Patritumab Deruxtecan in Patients with HER3 Expressing Advanced
-
Daiichi Sankyo2023-11-09 20:59:40Late-Breaking Data for Daiichi Sankyo’s HER3 Directed ADC Patritumab Deruxtecan in EGFR Mutated NSCLC to be
-
Daiichi Sankyo2023-11-09 20:58:33EMA Validates and Grants Accelerated Assessment for Trastuzumab Deruxtecan for the Treatment of HER2 Positive
-
Daiichi Sankyo2023-11-09 20:56:34ENHERTU® Demonstrated Meaningful Clinical Activity in Patients with HER2 Mutant Non-Small Cell Lung Cancer in
-
Daiichi Sankyo2023-11-09 20:56:43ENHERTU® Achieved a Tumor Response Rate of 45.3% in Patients with HER2 Positive Metastatic Colorectal Cancer
-
Daiichi Sankyo2023-11-09 20:56:52ENHERTU® Significantly Improved Tumor Response Rate and Overall Survival in HER2 Positive Metastatic Gastric
-
Daiichi Sankyo2023-11-09 20:57:08ENHERTU® Granted Orphan Drug Designation in the U.S. for Gastric Cancer
-
Daiichi Sankyo2020-08-03 09:22:50ENHERTU® Granted Breakthrough Therapy Designation in the U.S. for HER2 Mutant Metastatic Non-Small Cell Lung
-
Daiichi Sankyo2023-11-10 06:54:49ENHERTU® Granted Breakthrough Therapy Designation in the U.S. for HER2 Positive Metastatic Gastric Cancer